OP037 Risk of cancer in inflammatory bowel disease patients is associated with age and recent use of immunomodulators, while biologics and aminosalicylates are protective factors: a cross-sectional and follow-up analysis of the Swiss IBD cohort study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.